Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | CCR4 | P51679 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24717794 | 1.00 | HRH3 (0.42) | HRH3CCR4BCHEADRA1AACHE | |
| SCHEMBL2618405 | 0.86 | HRH3 (0.37) | HRH3CCR4BCHEADRA1AALDH1A1 | |
| SCHEMBL26936208 | 0.85 | ADRA1A (0.40) | HRH3ADRA1AALDH1A1 | |
| SCHEMBL24717539 | 0.83 | HRH3 (0.34) | HRH3CCR4ADRA1AALDH1A1DPP4 | |
| SCHEMBL24718209 | 0.83 | HRH3 (0.34) | HRH3 | |
| SCHEMBL24717540 | 0.83 | HRH3 (0.34) | HRH3CCR4ADRA1AALDH1A1DPP4 | |
| SCHEMBL29335361 | 0.83 | HRH3 (0.34) | HRH3 | |
| SCHEMBL13395779 | 0.81 | ALDH1A1 (0.51) | HRH3CCR4BCHEADRA1AACHE | |
| SCHEMBL24995530 | 0.81 | HRH3 (0.37) | HRH3ALDH1A1DPP4DPP7HSD11B1 | |
| SCHEMBL24718323 | 0.81 | HRH3 (0.37) | HRH3ALDH1A1DPP4DPP7HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | HRH3 3492/4885CCR4 2243/4885BCHE 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.